RU2010123028A - Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона - Google Patents
Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона Download PDFInfo
- Publication number
- RU2010123028A RU2010123028A RU2010123028/15A RU2010123028A RU2010123028A RU 2010123028 A RU2010123028 A RU 2010123028A RU 2010123028/15 A RU2010123028/15 A RU 2010123028/15A RU 2010123028 A RU2010123028 A RU 2010123028A RU 2010123028 A RU2010123028 A RU 2010123028A
- Authority
- RU
- Russia
- Prior art keywords
- epothilone
- treatment
- antidiarrheal agent
- patient
- derivative
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title claims abstract 4
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract 3
- 229960001334 corticosteroids Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 18
- 229940125714 antidiarrheal agent Drugs 0.000 claims abstract 17
- 239000003793 antidiarrheal agent Substances 0.000 claims abstract 17
- 150000003883 epothilone derivatives Chemical class 0.000 claims abstract 14
- 229960004618 prednisone Drugs 0.000 claims abstract 8
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims abstract 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract 7
- 239000003862 glucocorticoid Substances 0.000 claims abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 239000001257 hydrogen Substances 0.000 claims abstract 7
- 229930013356 epothilone Natural products 0.000 claims abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims abstract 3
- 229960003957 dexamethasone Drugs 0.000 claims abstract 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract 3
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims abstract 3
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical group C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 229960005205 prednisolone Drugs 0.000 claims abstract 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98663507P | 2007-11-09 | 2007-11-09 | |
| US60/986,635 | 2007-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010123028A true RU2010123028A (ru) | 2011-12-20 |
Family
ID=40087318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010123028/15A RU2010123028A (ru) | 2007-11-09 | 2008-10-15 | Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100267682A1 (https=) |
| EP (1) | EP2222286A1 (https=) |
| JP (1) | JP2011503075A (https=) |
| KR (1) | KR20100096077A (https=) |
| CN (1) | CN101848708B (https=) |
| AU (1) | AU2008325016A1 (https=) |
| BR (1) | BRPI0820338A2 (https=) |
| CA (1) | CA2703792A1 (https=) |
| MX (1) | MX2010005119A (https=) |
| RU (1) | RU2010123028A (https=) |
| WO (1) | WO2009061587A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201501870RA (en) | 2012-09-26 | 2015-04-29 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| SG10201907684PA (en) * | 2013-01-15 | 2019-10-30 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
| EP3519592B1 (en) * | 2016-09-27 | 2022-03-09 | Mayo Foundation for Medical Education and Research | Materials and methods for evaluating cancer |
| AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| US10705435B2 (en) | 2018-01-12 | 2020-07-07 | Globalfoundries Inc. | Self-referencing and self-calibrating interference pattern overlay measurement |
| US11686576B2 (en) | 2020-06-04 | 2023-06-27 | Kla Corporation | Metrology target for one-dimensional measurement of periodic misregistration |
| US11796925B2 (en) | 2022-01-03 | 2023-10-24 | Kla Corporation | Scanning overlay metrology using overlay targets having multiple spatial frequencies |
| US12032300B2 (en) | 2022-02-14 | 2024-07-09 | Kla Corporation | Imaging overlay with mutually coherent oblique illumination |
| US12422363B2 (en) | 2022-03-30 | 2025-09-23 | Kla Corporation | Scanning scatterometry overlay metrology |
| US12487190B2 (en) | 2022-03-30 | 2025-12-02 | Kla Corporation | System and method for isolation of specific fourier pupil frequency in overlay metrology |
| US12235588B2 (en) | 2023-02-16 | 2025-02-25 | Kla Corporation | Scanning overlay metrology with high signal to noise ratio |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1231894A (zh) * | 1998-04-14 | 1999-10-20 | 陈水清 | 止泻栓 |
| SK287334B6 (sk) * | 2001-03-19 | 2010-07-07 | Novartis Ag | Kombinácia protihnačkového činidla a epotilónu alebo jeho derivátu, farmaceutická kompozícia a obchodné balenie, ktoré ju obsahujú, a jej použitie |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| AU2003264822A1 (en) * | 2002-10-11 | 2004-05-04 | Dana-Farber Cancer Institute Inc | Epothilone derivatives for the treatment of multiple myeloma |
| CA2573949A1 (en) * | 2004-07-26 | 2006-02-02 | Novartis Ag | Epothilone combinations |
-
2008
- 2008-10-15 JP JP2010533139A patent/JP2011503075A/ja active Pending
- 2008-10-15 US US12/741,680 patent/US20100267682A1/en not_active Abandoned
- 2008-10-15 BR BRPI0820338A patent/BRPI0820338A2/pt not_active IP Right Cessation
- 2008-10-15 KR KR1020107010102A patent/KR20100096077A/ko not_active Withdrawn
- 2008-10-15 AU AU2008325016A patent/AU2008325016A1/en not_active Abandoned
- 2008-10-15 CN CN2008801149548A patent/CN101848708B/zh not_active Expired - Fee Related
- 2008-10-15 RU RU2010123028/15A patent/RU2010123028A/ru not_active Application Discontinuation
- 2008-10-15 CA CA2703792A patent/CA2703792A1/en not_active Abandoned
- 2008-10-15 EP EP08848076A patent/EP2222286A1/en not_active Withdrawn
- 2008-10-15 MX MX2010005119A patent/MX2010005119A/es not_active Application Discontinuation
- 2008-10-15 WO PCT/US2008/079936 patent/WO2009061587A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011503075A (ja) | 2011-01-27 |
| AU2008325016A1 (en) | 2009-05-14 |
| BRPI0820338A2 (pt) | 2017-05-02 |
| EP2222286A1 (en) | 2010-09-01 |
| WO2009061587A1 (en) | 2009-05-14 |
| US20100267682A1 (en) | 2010-10-21 |
| CN101848708A (zh) | 2010-09-29 |
| CA2703792A1 (en) | 2009-05-14 |
| KR20100096077A (ko) | 2010-09-01 |
| MX2010005119A (es) | 2010-05-27 |
| CN101848708B (zh) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010123028A (ru) | Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона | |
| US20240238298A1 (en) | JAK Inhibitors for Managing Conditions in Patients with Down's Syndrome or Other Trisomy | |
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP2011511071A5 (https=) | ||
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| JP5897592B2 (ja) | 葉酸−ラミプリルの組合せ：細胞保護性、神経保護性、および網膜保護性の眼科用組成物 | |
| WO2010081817A1 (en) | Method for treating colorectal cancer | |
| US20100093754A1 (en) | Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders | |
| CY1108309T1 (el) | Διαμορφωτες πυρηνικων υποδοχεων τρικυκλικων στεροειδων ορμονων | |
| JP2017537089A5 (https=) | ||
| JP2009542623A (ja) | Ｈ２遮断薬、少なくとも１つの抗炎症薬剤および細胞毒性薬剤を含む抗がん治療 | |
| JP2011503075A5 (https=) | ||
| EP2670405B1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| WO2001060370A1 (en) | Remedies for endothelin-induced diseases | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| US11672790B2 (en) | Methods of managing conditioned fear with neurokinin receptor antagonists | |
| CN115397415A (zh) | 乳腺癌治疗剂 | |
| CN114599352A (zh) | 用于治疗癌症的α-甲基-DL-酪氨酸烷基酯 | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| CN111629727A (zh) | 用于治疗血液肿瘤和实体癌的钙释放活化钙通道调节剂 | |
| Lynn | Fulvestrant (‘Faslodex’)—a new hormonal treatment for advanced breast cancer | |
| RU2362564C1 (ru) | Способ медикаментозной коррекции 2 стадии желчекаменной болезни у пациентов с описторхозом | |
| TW200902028A (en) | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases | |
| WO2004062687A1 (en) | Pharmaceutical composition for cancer treatment containing p43 protein and paclitaxel, therapy method using the same and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130426 |